Table 3 Performance of clinical assessment to predict the need for 2nd TURB in the total cohort.
From: Xpert bladder cancer monitor to predict the need for a second TURB (MoniTURB trial)
Group | n | TP | FP | TN | FN | Sensitivity | Specificity | HG | LG | PPV | NPV |
|---|---|---|---|---|---|---|---|---|---|---|---|
(a) Clinical assessment by treating physician’s discretion | |||||||||||
Control cystoscopy | 57 | 0 | 0 | 55 | 2 | 0/2 (0%) | 55/55 (100%) | 0/2 (0%) | 55/57 (96.5%) | ||
2nd TURB | 114 | 34 | 80 | 0 | 0 | 34/34 (100%) | 0/80 (0%) | 28/28 (100%) | 6/6 (100%) | 34/114 (29.8%) | |
Total | 171 | 34 | 80 | 55 | 2 | 34/36 (94.4%) | 55/135 (40.7%) | 28/28 (100%) | 6/8 (75%) | 34/114 (29.8%) | 55/57 (96.5%) |
(b) Clinical assessment in pTa tumors by physician’s discretion | |||||||||||
Control cystoscopy | 55 | 0 | 0 | 53 | 2 | 0/2 (0%) | 53/53 (100%) | 0/2 (100%) | 53/55 (96.4%) | ||
2nd TURB | 60 | 15 | 45 | 0 | 0 | 15/15 (97.1%) | 0/45 (0%) | 11/11 (100%) | 4/4 (66.7%) | 15/60 (25%) | |
Total | 115 | 15 | 45 | 53 | 2 | 15/17 (88.2%) | 53/98 (54.1%) | 11/11 (100%) | 4/6 (66.7%) | 15/60 (25%) | 53/55 (96.4%) |
